Skip to main content
. 2017 Mar 7;8(17):29013–29027. doi: 10.18632/oncotarget.15994

Figure 2. ST3GalI interacts with EGFR signaling pathway in ovarian cancer.

Figure 2

(A) The correlation of 20 STs and significant cell receptors in the ES2ovarian cancer cell line were analyzed by the L1000 mRNA microarray. Data shown are mean ± SD of separate repeat experiments. (B) The analysis of mRNA expression of ST3GalI and EGFR from Oncomine TCGA (n=562), Bittner (n=241), and Lu (n=50) ovarian cancer genomics is shown. The expression of EGFR was compared between low and high ST3GalI groups using a tercile approach. (C) The mRNA expression of α2,3-sialyltransferases and TKI drug efficiency (Actarea) are shown from the CCLE ovarian cancer dataset. (D-E) Western blot analysis of EGFR and phospho-EGFR in ST3GalI knocked-down or overexpressing cells compared to controls is shown. GAPDH was used as control (same GAPDH as in Figure 1D-1E). (F) The co-immunoprecipitation assay coupled with immunoblotting analysis to evaluate the protein-protein interaction of ST3GalI and EGFR is shown. (G) Immunoblotting of ST3Ga1I immunoprecipitated with anti-EGFR antibodies in SC and ST3GalI knock-down of ES2 cell line are shown. (H) Time course RNA and protein analysis showing EGFR expression during ST3GalI knock-down.